Conference Coverage

CAR T in DLBCL: Liso-cel has ‘remarkable’ efficacy in cohort

Publish date: June 27, 2018

 

REPORTING FROM ASCO 2018

SOURCE: Abramson JS et al. ASCO 2018. Abstract 7505.

Pages

Recommended Reading

Adding bortezomib does not improve MCL outcomes
B-Cell Lymphoma ICYMI
Overcoming TP53 mutation proves difficult in MCL
B-Cell Lymphoma ICYMI
Novel antibody shifts ‘eat me/don’t eat me’ balance in refractory NHL
B-Cell Lymphoma ICYMI
Chemo-free regimen appears viable in previously untreated FL
B-Cell Lymphoma ICYMI
British good practice paper offers MCL diagnosis pearls
B-Cell Lymphoma ICYMI
DLBCL survival improved with novel antibody-drug conjugate
B-Cell Lymphoma ICYMI
Inhibitor exhibits activity in B- and T-cell NHLs
B-Cell Lymphoma ICYMI
‘Excellent’ survival with HCT despite early treatment failure in FL
B-Cell Lymphoma ICYMI
Chemo-free combo provides potential first-line option for FL
B-Cell Lymphoma ICYMI
Polatuzumab plus BR improves efficacy in DLBCL
B-Cell Lymphoma ICYMI